This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Oct 4;372(9645):1197-8.

doi: 10.1016/S0140-6736(08)61207-6. Epub 2008 Sep 7.

Exenatide once weekly in type 2 diabetes

Andre J Scheen¹

Affiliations

Affiliation

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liège, B-4000 Liège, Belgium. andre.scheen@chu.ulg.ac.be

PMID: 18782642
DOI: 10.1016/S0140-6736(08)61207-6

Free article

Comment

Exenatide once weekly in type 2 diabetes

Andre J Scheen. Lancet. 2008.

Free article

. 2008 Oct 4;372(9645):1197-8.

doi: 10.1016/S0140-6736(08)61207-6. Epub 2008 Sep 7.

Author

Andre J Scheen¹

Affiliation

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liège, B-4000 Liège, Belgium. andre.scheen@chu.ulg.ac.be

PMID: 18782642
DOI: 10.1016/S0140-6736(08)61207-6

No abstract available

PubMed Disclaimer

Comment on

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; DURATION-1 Study Group. Drucker DJ, et al. Lancet. 2008 Oct 4;372(9645):1240-50. doi: 10.1016/S0140-6736(08)61206-4. Epub 2008 Sep 7. Lancet. 2008. PMID: 18782641 Clinical Trial.

Similar articles

Exenatide (Byetta) for type 2 diabetes.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2005 Jun 6;47(1210):45-6. Med Lett Drugs Ther. 2005. PMID: 15933616
Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
Minze MG, Klein MS, Jernigan MJ, Wise SL, Frugé K. Minze MG, et al. Pharmacotherapy. 2013 Jun;33(6):627-38. doi: 10.1002/phar.1240. Epub 2013 Apr 1. Pharmacotherapy. 2013. PMID: 23553357 Review.
Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M, Harris K, Brackett A. Tzefos M, et al. Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Ann Pharmacother. 2012. PMID: 22232377 Review.
Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
Shaw JE, Gallwitz B, Han J, Hardy E, Schernthaner G. Shaw JE, et al. Diabetes Obes Metab. 2017 Dec;19(12):1793-1797. doi: 10.1111/dom.13022. Epub 2017 Jul 25. Diabetes Obes Metab. 2017. PMID: 28573708 Free PMC article.
Time for clinically relevant comparative effectiveness studies in type 2 diabetes.
Nathan DM. Nathan DM. Ann Intern Med. 2011 Jan 18;154(2):131-2. doi: 10.7326/0003-4819-154-2-201101180-00303. Epub 2010 Dec 6. Ann Intern Med. 2011. PMID: 21135287 No abstract available.

See all similar articles

Cited by

Rosiglitazone: to be or not to be?
Scheen AJ. Scheen AJ. Diabetologia. 2009 Jul;52(7):1448-50. doi: 10.1007/s00125-009-1358-z. Epub 2009 Apr 18. Diabetologia. 2009. PMID: 19377889 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information